Treace Medical Concepts, Inc. (TMCI) Shareholders May Have Been Affected by Fraud - Levi & Korsinsky Investigates ...

The Schall Law Firm Invites Shareholders With Losses To Join An Inquiry Into Treace Medical Concepts, Inc. For Securities Law Violations ...

Company Investigation - Levi & Korsinsky is investigating whether Treace Medical Concepts Inc (TMCI) misled investors [1] - The investigation focuses on potential misleading statements or omissions by the company [1] - Shareholder rights advocates are involved in the probe [1] Legal Context - The investigation is being conducted by a law firm specializing in shareholder rights [1] - The probe is in its early stages with no conclusions yet [1] - The investigation could potentially lead to legal action if wrongdoing is found [1]

Treace Medical Concepts, Inc. Is Being Investigated For Securities Law Violations And Affected Investors Are Urged To Contact The Schall Law Firm ...

The Schall Law Firm Invites Shareholders With Losses To Join An Inquiry Into Treace Medical Concepts, Inc. For Securities Fraud ...

FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 13, 2025 TREACE MEDICAL CONCEPTS, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation) (Commission File Number) Delaware 001-40355 47-1052611 (IRS Employer Identification Number) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Indicate by check mark whether the registrant is an em ...

PONTE VEDRA, Fla., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced its preliminary, unaudited fourth quarter and full-year 2024 results. Highlights: Preliminary revenue of $68.4 million to $68.8 million in the fourth quarter of 2024, an approxi ...

Treace Medical Concepts, Inc. (TMCI) recently announced the limited market release and first surgical cases utilizing the Percuplasty Percutaneous 3D Bunion Correction System and Procedure.This development follows Treace Medical's recent introduction of the Adductoplasty Midfoot Correction System, designed for reproducible surgical correction of midfoot deformities, and the SpeedPlate Rapid Compression Implants, an innovative fixation platform versatile across various foot procedures.The Percuplasty Percuta ...

PONTE VEDRA, Fla., Jan. 02, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced that John T. Treace, Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025, beginning at approximately 9:00 am ...

Company Overview - Treace Medical Concepts Inc is a medical technology company focused on advancing the surgical management of bunion and related midfoot deformities [13] - The company has pioneered and patented the Lapiplasty 3D Bunion Correction System, which addresses the root cause of bunions [13] - Treace estimates that 1 1 million of the 67 million Americans affected by bunions are annual surgical candidates [13] - The company has introduced additional products including the Adductoplasty Midfoot Correction System and SpeedPlate Rapid Compression Implants [13] Product Development - The Percuplasty Percutaneous 3D Bunion Correction System represents the company's second entry into the metatarsal osteotomy segment, which accounts for approximately 70% of the 450,000 bunion surgeries performed annually in the US [2] - Full commercialization of the Percuplasty System is anticipated in the second half of 2025 [10] - The Percuplasty System follows the limited release of the Nanoplasty System, providing an additional solution in the large metatarsal osteotomy segment of the $5B+ US bunion market opportunity [12] Market Strategy - The limited market release of the Percuplasty System positions the company to significantly increase its share of the overall bunion market and expand its surgeon customer base [17] - The company aims to provide a comprehensive portfolio of instrumented 3D bunion systems to meet the evolving needs of surgeons and patients [12] - The Percuplasty System is designed to expand surgeon and patient access to the improved recovery and cosmetic benefits of percutaneous bunion surgery [15] Industry Context - Bunions are complex 3-dimensional deformities that originate from an unstable joint in the middle of the foot [13] - The metatarsal osteotomy segment is the largest segment of the bunion market [2] - There is growing patient demand for minimally invasive (MIS) bunion surgery [15]